118 related articles for article (PubMed ID: 38180342)
21. Elevated APOBEC mutational signatures implicate chronic injury in etiology of an aggressive head-and-neck squamous cell carcinoma: a case report.
Patel J; den Breems NY; Tuluc M; Johnson J; Curry JM; South AP; Cho RJ
J Med Case Rep; 2021 Apr; 15(1):252. PubMed ID: 33926553
[TBL] [Abstract][Full Text] [Related]
22. Targeted Deep Sequencing of Bladder Tumors Reveals Novel Associations between Cancer Gene Mutations and Mutational Signatures with Major Risk Factors.
Koutros S; Rao N; Moore LE; Nickerson ML; Lee D; Zhu B; Pardo LA; Baris D; Schwenn M; Johnson A; Jones K; Garcia-Closas M; Prokunina-Olsson L; Silverman DT; Rothman N; Dean M
Clin Cancer Res; 2021 Jul; 27(13):3725-3733. PubMed ID: 33849962
[TBL] [Abstract][Full Text] [Related]
23. Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study.
Shi J; Hua X; Zhu B; Ravichandran S; Wang M; Nguyen C; Brodie SA; Palleschi A; Alloisio M; Pariscenti G; Jones K; Zhou W; Bouk AJ; Boland J; Hicks B; Risch A; Bennett H; Luke BT; Song L; Duan J; Liu P; Kohno T; Chen Q; Meerzaman D; Marconett C; Laird-Offringa I; Mills I; Caporaso NE; Gail MH; Pesatori AC; Consonni D; Bertazzi PA; Chanock SJ; Landi MT
PLoS Med; 2016 Dec; 13(12):e1002162. PubMed ID: 27923066
[TBL] [Abstract][Full Text] [Related]
24. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool.
Poon SL; Pang ST; McPherson JR; Yu W; Huang KK; Guan P; Weng WH; Siew EY; Liu Y; Heng HL; Chong SC; Gan A; Tay ST; Lim WK; Cutcutache I; Huang D; Ler LD; Nairismägi ML; Lee MH; Chang YH; Yu KJ; Chan-On W; Li BK; Yuan YF; Qian CN; Ng KF; Wu CF; Hsu CL; Bunte RM; Stratton MR; Futreal PA; Sung WK; Chuang CK; Ong CK; Rozen SG; Tan P; Teh BT
Sci Transl Med; 2013 Aug; 5(197):197ra101. PubMed ID: 23926199
[TBL] [Abstract][Full Text] [Related]
25. Molecular Genetic Features of Primary Nonurachal Enteric-type Adenocarcinoma, Urachal Adenocarcinoma, Mucinous Adenocarcinoma, and Intestinal Metaplasia/Adenoma: Review of the Literature and Next-generation Sequencing Study.
Pires-Luis AS; Martinek P; Alaghehbandan R; Trpkov K; Comperat EM; Perez Montiel DM; Bulimbasic S; Lobo J; Henrique R; Vanecek T; Pivovarcikova K; Michalova K; Pitra T; Hora M; Marques A; Lopes JM; Rogala J; Mareckova J; Michal M; Hes O
Adv Anat Pathol; 2020 Sep; 27(5):303-310. PubMed ID: 32520749
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive
Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
Front Immunol; 2022; 13():931906. PubMed ID: 35958598
[TBL] [Abstract][Full Text] [Related]
27. Characterization of genomic alterations and neoantigens and analysis of immune infiltration identified therapeutic and prognostic biomarkers in adenocarcinoma at the gastroesophageal junction.
Lao Y; Wang Y; Yang J; Liu T; Ma Y; Luo Y; Sun Y; Li K; Zhao X; Niu X; Xi Y; Zhong C
Front Oncol; 2022; 12():941868. PubMed ID: 36439494
[TBL] [Abstract][Full Text] [Related]
28. Mutational signature of aristolochic acid: Clue to the recognition of a global disease.
Rosenquist TA; Grollman AP
DNA Repair (Amst); 2016 Aug; 44():205-211. PubMed ID: 27237586
[TBL] [Abstract][Full Text] [Related]
29. Multi-Omics analysis identifies a lncRNA-related prognostic signature to predict bladder cancer recurrence.
Xu Z; Chen H; Sun J; Mao W; Chen S; Chen M
Bioengineered; 2021 Dec; 12(2):11108-11125. PubMed ID: 34738881
[TBL] [Abstract][Full Text] [Related]
30. Anterior wall adenocarcinoma of bladder with similar clinicopathological and prognostic characteristics as common bladder carcinomas should not be treated as or classified into urachal adenocarcinomas.
Zhou YW; Long YX; Song K; Liang LB; Cheng K; Chen Y; Liu JY
Cancer Med; 2021 Aug; 10(16):5415-5428. PubMed ID: 34278741
[TBL] [Abstract][Full Text] [Related]
31. Identification of distinct mutational patterns and new driver genes in oesophageal squamous cell carcinomas and adenocarcinomas.
Lin DC; Dinh HQ; Xie JJ; Mayakonda A; Silva TC; Jiang YY; Ding LW; He JZ; Xu XE; Hao JJ; Wang MR; Li C; Xu LY; Li EM; Berman BP; Phillip Koeffler H
Gut; 2018 Oct; 67(10):1769-1779. PubMed ID: 28860350
[TBL] [Abstract][Full Text] [Related]
32. An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer.
Lindskrog SV; Prip F; Lamy P; Taber A; Groeneveld CS; Birkenkamp-Demtröder K; Jensen JB; Strandgaard T; Nordentoft I; Christensen E; Sokac M; Birkbak NJ; Maretty L; Hermann GG; Petersen AC; Weyerer V; Grimm MO; Horstmann M; Sjödahl G; Höglund M; Steiniche T; Mogensen K; de Reyniès A; Nawroth R; Jordan B; Lin X; Dragicevic D; Ward DG; Goel A; Hurst CD; Raman JD; Warrick JI; Segersten U; Sikic D; van Kessel KEM; Maurer T; Meeks JJ; DeGraff DJ; Bryan RT; Knowles MA; Simic T; Hartmann A; Zwarthoff EC; Malmström PU; Malats N; Real FX; Dyrskjøt L
Nat Commun; 2021 Apr; 12(1):2301. PubMed ID: 33863885
[TBL] [Abstract][Full Text] [Related]
33. Analysis of Intestinal Metaplasia Without Dysplasia in the Urinary Bladder Reveal Only Rare Mutations Associated With Colorectal Adenocarcinoma.
Amin A; Murati-Amador B; Lombardo KA; Jackson CL; Grada Z; Palsgrove DN; Matoso A
Appl Immunohistochem Mol Morphol; 2020; 28(10):786-790. PubMed ID: 31876604
[TBL] [Abstract][Full Text] [Related]
34. Integrative transcriptional characterization of cell cycle checkpoint genes promotes clinical management and precision medicine in bladder carcinoma.
Shi WW; Guan JZ; Long YP; Song Q; Xiong Q; Qin BY; Ma ZQ; Hu Y; Yang B
Front Oncol; 2022; 12():915662. PubMed ID: 36033441
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance and immune landscape of a fatty acid metabolism-related gene signature in colon adenocarcinoma.
Liu X; Fang X; Lu L; Liu G
Front Genet; 2022; 13():996625. PubMed ID: 36568396
[No Abstract] [Full Text] [Related]
36. In-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors.
Boot A; Huang MN; Ng AWT; Ho SC; Lim JQ; Kawakami Y; Chayama K; Teh BT; Nakagawa H; Rozen SG
Genome Res; 2018 May; 28(5):654-665. PubMed ID: 29632087
[TBL] [Abstract][Full Text] [Related]
37. Elaboration and validation of a prognostic signature associated with disulfidoptosis in lung adenocarcinoma, consolidated with integration of single-cell RNA sequencing and bulk RNA sequencing techniques.
He D; Tang H; Yang X; Liu X; Zhang Y; Shi J
Front Immunol; 2023; 14():1278496. PubMed ID: 37965333
[TBL] [Abstract][Full Text] [Related]
38. Whole exome sequencing of urachal adenocarcinoma reveals recurrent NF1 mutations.
Singh H; Liu Y; Xiao X; Lin L; Kim J; Van Hummelen P; Wu CL; Bass AJ; Saylor PJ
Oncotarget; 2016 May; 7(20):29211-5. PubMed ID: 27078850
[TBL] [Abstract][Full Text] [Related]
39. CD8 lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors.
Deng B; Park JH; Ren L; Yew PY; Kiyotani K; Antic T; O'Connor K; O'Donnell PH; Nakamura Y
Cancer Rep (Hoboken); 2018 Jun; 1(1):e1002. PubMed ID: 32729250
[TBL] [Abstract][Full Text] [Related]
40. Age-related mutational signature negatively associated with immune activity and survival outcome in triple-negative breast cancer.
Chen H; Chong W; Yang X; Zhang Y; Sang S; Li X; Lu M
Oncoimmunology; 2020 Jun; 9(1):1788252. PubMed ID: 32923150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
